{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:47:34Z","timestamp":1782330454555,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,5,20]],"date-time":"2009-05-20T00:00:00Z","timestamp":1242777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s12185-009-0326-1","type":"journal-article","created":{"date-parts":[[2009,5,19]],"date-time":"2009-05-19T04:22:54Z","timestamp":1242706974000},"page":"664-672","source":"Crossref","is-referenced-by-count":22,"title":["Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"89","author":[{"given":"Dong-Wook","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeow-Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hua","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla B.","family":"Caguioa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brigid","family":"Bradley-Garelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydip","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saengsuree","family":"Jootar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,5,20]]},"reference":[{"key":"326_CR1","unstructured":"Ries LAG, Melbert D, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975\u20132005, National Cancer Institute. Bethesda, http:\/\/seer.cancer.gov\/csr\/1975_2005\/ , based on November 2007 SEER data submission, posted to the SEER web site, 2008."},{"key":"326_CR2","doi-asserted-by":"crossref","unstructured":"Wing YA, Priscilla BC, Chuah C, et al. Chronic myeloid leukemia in Asia. Int. J Hematol. 2009;89:14\u201323. doi: 10.1007\/s12185-008-0230-0 .","DOI":"10.1007\/s12185-008-0230-0"},{"key":"326_CR3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","volume":"101","author":"H Kantarjian","year":"2003","unstructured":"Kantarjian H, Talpaz M, O\u2019Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473\u20135. doi: 10.1182\/blood-2002-05-1451 .","journal-title":"Blood"},{"key":"326_CR4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brian S, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317. doi: 10.1056\/NEJMoa062867 .","journal-title":"N Engl J Med"},{"key":"326_CR5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000111777","volume":"118","author":"SJ Park","year":"2007","unstructured":"Park SJ, Choi IK, Seo HY, et al. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Acta Haematol. 2007;118:219\u201321. doi: 10.1159\/000111777 .","journal-title":"Acta Haematol"},{"key":"326_CR6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0145-2126(03)00101-2","volume":"27","author":"A Horikoshi","year":"2003","unstructured":"Horikoshi A, Takei K, Sawada S. Effects of lower dose of imatinib to CML patients. Leukemia Res. 2003;27:1167. doi: 10.1016\/S0145-2126(03)00101-2 .","journal-title":"Leukemia Res"},{"key":"326_CR7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.leukres.2006.05.019","volume":"31","author":"A Horikoshi","year":"2007","unstructured":"Horikoshi A, Takei K, Sawada S. Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic phase chronic myeloid leukemia (CML). Leukemia Res. 2007;31:569\u201375. doi: 10.1016\/j.leukres.2006.05.019 .","journal-title":"Leukemia Res"},{"key":"326_CR8","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496\u20139. doi: 10.1182\/blood-2006-07-036012 .","journal-title":"Blood"},{"key":"326_CR9","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022\u20138. doi: 10.1182\/blood-2007-10-116475 .","journal-title":"Blood"},{"key":"326_CR10","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66:5790\u20137. doi: 10.1158\/0008-5472.CAN-05-4187 .","journal-title":"Cancer Res"},{"key":"326_CR11","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500\u20135. doi: 10.1158\/0008-5472.CAN-05-0259 .","journal-title":"Cancer Res"},{"key":"326_CR12","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658\u201361. doi: 10.1021\/jm049486a .","journal-title":"J Med Chem"},{"key":"326_CR13","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","volume":"65","author":"S Nam","year":"2005","unstructured":"Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65:9185\u20139. doi: 10.1158\/0008-5472.CAN-05-1731 .","journal-title":"Cancer Res"},{"key":"326_CR14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341. doi: 10.1056\/NEJMoa055229 .","journal-title":"N Engl J Med"},{"key":"326_CR15","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303\u20139. doi: 10.1182\/blood-2006-09-047266 .","journal-title":"Blood"},{"key":"326_CR16","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143\u201350. doi: 10.1182\/blood-2006-09-046839 .","journal-title":"Blood"},{"key":"326_CR17","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207\u201313. doi: 10.1182\/blood-2006-09-046888 .","journal-title":"Blood"},{"key":"326_CR18","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143\u201350. doi: 10.1182\/blood-2006-11-056028 .","journal-title":"Blood"},{"key":"326_CR19","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","volume":"110","author":"O Ottmann","year":"2007","unstructured":"Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood. 2007;110:2309\u201315. doi: 10.1182\/blood-2007-02-073528 .","journal-title":"Blood"},{"key":"326_CR20","doi-asserted-by":"crossref","unstructured":"Dai G, Pfister M, Blackwood-Chirchir A, Roy A. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacol. 2008 (Epub ahead of print).","DOI":"10.1177\/0091270008320604"},{"key":"326_CR21","unstructured":"SPRYCEL\u00ae (dasatinib) [package insert]. Princeton: Bristol-Myers Squibb Company; 2008."},{"key":"326_CR22","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908\u201314. doi: 10.1200\/JCO.2007.12.0329 .","journal-title":"J Clin Oncol"},{"key":"326_CR23","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib (100\u00a0mg once daily) preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204\u201312. doi: 10.1200\/JCO.2007.14.9260 .","journal-title":"J Clin Oncol"},{"key":"326_CR24","doi-asserted-by":"crossref","unstructured":"Wang X, Hochhaus A, Kantarjian HM, et al. Dasatinib pharmacokinetics and exposure-response: relationship to safety and efficacy in patients with chronic myeloid leukemia. J Clin Oncol. 2008;26S:175s. abstract 3590.","DOI":"10.1200\/jco.2008.26.15_suppl.3590"},{"key":"326_CR25","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/1097-0142(20011115)92:10<2501::AID-CNCR1600>3.0.CO;2-N","volume":"92","author":"HM Kantarjian","year":"2001","unstructured":"Kantarjian HM, Shan J, Smith T, et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 2001;92:2501\u20137. doi: 10.1002\/1097-0142(20011115)92:10<2501::AID-CNCR1600>3.0.CO;2-N .","journal-title":"Cancer"},{"key":"326_CR26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.hoc.2004.03.005","volume":"18","author":"FJ Giles","year":"2004","unstructured":"Giles FJ, Cortes JE, Kantarjian HM, O\u2019Brien SM. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:753\u201374. doi: 10.1016\/j.hoc.2004.03.005 .","journal-title":"Hematol Oncol Clin North Am"},{"key":"326_CR27","doi-asserted-by":"crossref","unstructured":"Sakamaki H, Ishizawa K, Taniwaki M, et al. Dasatinib phase I\/II study of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib: Results of the CA180031 study in Japan. J Clin Oncol. 2007;25(18S):681s. abstract 17515.","DOI":"10.1200\/jco.2007.25.18_suppl.17515"},{"key":"326_CR28","doi-asserted-by":"crossref","unstructured":"Wang L, Christopher LJ, Cui D, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib. An effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 (epub ahead of print).","DOI":"10.1124\/dmd.107.020255"},{"key":"326_CR29","unstructured":"Eley T, Varga A, Sanil J, et al. The effects of rifampin on the pharmacokinetics of dasatinib and two metabolites in healthy subjects. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting 2006. Abstract 003076."},{"key":"326_CR30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1349-7006.2008.00744.x","volume":"99","author":"S Lal","year":"2008","unstructured":"Lal S, Wong ZW, Sandanaraj E, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99:816\u201323. doi: 10.1111\/j.1349-7006.2008.00744.x .","journal-title":"Cancer Sci."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0326-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-009-0326-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0326-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T08:56:38Z","timestamp":1589792198000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-009-0326-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,20]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["326"],"URL":"https:\/\/doi.org\/10.1007\/s12185-009-0326-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,20]]}}}